Evidence map›Paper›PMID 34154921›Full record

ArticleJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2021

Development of a genotyping platform for SARS-CoV-2 variants using high-resolution melting analysis.

Akira Aoki, Yoko Mori, Yoshinori Okamoto, Hideto Jinno

Open access · bronzeAbstract read
In one paragraph

Article in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Akira AokiFaculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-Ku, Nagoya, 468-8503, Japan.
Yoko MoriFaculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-Ku, Nagoya, 468-8503, Japan.
Yoshinori OkamotoFaculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-Ku, Nagoya, 468-8503, Japan.
Hideto JinnoFaculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-Ku, Nagoya, 468-8503, Japan. Electronic address: jinno@meijo-u.ac.jp.
Meijo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus causing coronavirus disease 2019 (COVID-19), has been expanding globally since late 2019. SARS-CoV-2, an RNA virus, has a genome sequence that can easily undergo mutation. Several mutated SARS-CoV-2 strains, including those with higher infectivity than others, have been reported. To reduce SARS-CoV-2 transmission, it is crucial to trace its infection sources. Here, we developed a simple, easy-to-use genotyping method to identify SARS-CoV-2 variants using a high-resolution melting (HRM) analysis.

methodsWe investigated five mutation sites, A23403G, G25563T, G26144T, T28144C, and G28882A, which are known strain determinants according to GISAID clades (L, S, V, G, GH, and GR).

resultsWe first employed synthetic DNA fragments containing the five characteristic sites for HRM analysis. All sequences clearly differentiated wild-type from mutant viruses. We then confirmed that RNA fragments were suitable for HRM analysis following reverse transcription. Human saliva did not negatively affect the HRM analysis, which supports the absence of a matrix effect.

conclusionsOur results indicate that this HRM-based genotyping method can identify SARS-CoV-2 variants. This novel assay platform potentially paves the way for accurate and rapid identification of SARS-CoV-2 infection sources.

Indexed as

COVID-19SARS-CoV-2GenotypeGenotyping TechniquesHumansCOVID-19Genotyping methodHigh resolution meltingReal-time PCRSARS-CoV-2Virus mutation

Identifiers

PMID34154921
PMCPMC8196315
OpenAlexW3167550518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.